Narayan, Rajiv

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell

Gene expression and cancer classificationBioinformatics and Genomic Networks

Cited by 3,515

Discovering the anticancer potential of non-oncology drugs by systematic viability profiling

Corsello, S. M., Nagari, R. T., Spangler, R. D., Rossen, J., Kocak, M., Bryan, J. G., Humeidi, R., Peck, D., Wu, X., Tang, A. A., et al. (2020) · Nature Cancer

Computational Drug Discovery MethodsCancer Cells and Metastasis

Cited by 878

A melanocyte lineage program confers resistance to MAP kinase pathway inhibition

Johannessen, C. M., Johnson, L. A., Piccioni, F., Townes, A., Frederick, D. T., Donahue, M. K., Narayan, R., Flaherty, K. T., Wargo, J. A., Root, D. E., et al. (2013) · Nature

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 452

Toward performance-diverse small-molecule libraries for cell-based phenotypic screening using multiplexed high-dimensional profiling

Wawer, M. J., Li, K., Gustafsdottir, S. M., Ljosa, V., Bodycombe, N. E., Marton, M. A., Sokolnicki, K. L., Bray, M.-A., Kemp, M. M., Winchester, E., et al. (2014) · Proceedings of the National Academy of Sciences

Computational Drug Discovery MethodsCell Image Analysis Techniques

Cited by 196

Abstract LB422: Selective targeting of CDK2 using molecular glue degraders for the treatment of HR-positive/HER2-negative breast cancer

Gkountela, S., Tahaney, W., Vafeiadou, V., Bianda, C., Cheeseman, L., Singh, A., Diesslin, A., Schillo, M., Nguyen, S., Moccia, L., et al. (2025) · Cancer Research

Protein Degradation and InhibitorsAdvanced Breast Cancer Therapies

Cited by 7